HLA-B27

Specialist

also human leukocyte antigen b27

What it isA class I HLA allele encoding a cell-surface protein that presents peptides to T cells. The allele is present in roughly 8% of people of European descent and has the strongest known association with axial spondyloarthritis.

DoesModifies T cell recognition of self and microbial peptides; thought to contribute to autoreactive immune responses in genetically primed people.

GoodAbsence of HLA-B27 makes ankylosing spondylitis and related spondyloarthritides very unlikely as the cause of inflammatory back pain.

BadPresence of HLA-B27 substantially raises the risk of ankylosing spondylitis, reactive arthritis, anterior uveitis, and inflammatory bowel-related arthritis. Most carriers never develop disease — it is a permissive factor, not a guarantee.

Standard

Positive or negative.

Optimal

No widely-accepted optimal — the genotype is fixed; goal is early recognition and aggressive treatment of any associated disease.

Modifiers

One-time test; genotype does not change.

How to optimize

Lifestyle: Regular spine-mobility exercise and posture work preserve in carriers who develop disease; smoking accelerates spondyloarthritis progression.
Diet: Mediterranean anti-inflammatory pattern; some carriers report benefit from low-starch diets but evidence is limited.
Supplements: Omega-3 EPA+DHA 2–4 g/day, vitamin D3 if deficient, curcumin 500 mg twice daily.
Peptides: BPC-157, TB-500, Thymosin Alpha-1 in inflammatory joint and tendon contexts.
Drugs: NSAIDs first-line for symptomatic disease; TNF and IL-17 inhibitors for moderate-to-severe spondyloarthritis.

within Genetic